JP2016074736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016074736A5 JP2016074736A5 JP2016014128A JP2016014128A JP2016074736A5 JP 2016074736 A5 JP2016074736 A5 JP 2016074736A5 JP 2016014128 A JP2016014128 A JP 2016014128A JP 2016014128 A JP2016014128 A JP 2016014128A JP 2016074736 A5 JP2016074736 A5 JP 2016074736A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- following structure
- cell
- composition
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 102000004591 Telomerase Human genes 0.000 claims 5
- 108010017842 Telomerase Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- 230000036912 Bioavailability Effects 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
Description
(実施例3 比較効力およびバイオアベイラビリティー研究)
非結合オリゴヌクレオチドとともに本発明の2系統の化合物を、個々の詳細な研究のために選択した。選択した化合物(図9に示される)は、以下のとおりであった:
化合物A(非結合):配列TAGGGTTAGACAA(この配列は、hTR(配列番号1)の42〜54塩基に対して相補的である)のチオホスホラミデートオリゴヌクレオチド(図9A)
化合物B:3’パルミトイルアミドに結合した化合物Aのオリゴヌクレオチド(図9B)
化合物C:5’−パルミトイルアミド−アミノグリセロール−チオホスフェートに結合した化合物Aのオリゴヌクレオチド(図9C)。
これらの化合物の研究を、本実施例および以下の実施例で報告する。
非結合オリゴヌクレオチドとともに本発明の2系統の化合物を、個々の詳細な研究のために選択した。選択した化合物(図9に示される)は、以下のとおりであった:
化合物A(非結合):配列TAGGGTTAGACAA(この配列は、hTR(配列番号1)の42〜54塩基に対して相補的である)のチオホスホラミデートオリゴヌクレオチド(図9A)
化合物B:3’パルミトイルアミドに結合した化合物Aのオリゴヌクレオチド(図9B)
化合物C:5’−パルミトイルアミド−アミノグリセロール−チオホスフェートに結合した化合物Aのオリゴヌクレオチド(図9C)。
これらの化合物の研究を、本実施例および以下の実施例で報告する。
Claims (11)
- テロメラーゼ酵素の活性をインビトロで阻害する方法であって、該方法は、該テロメラーゼ酵素と、以下の構造:
- テロメラーゼ酵素の活性を阻害するための組成物であって、以下の構造:
- 細胞内においてテロメラーゼ酵素の活性をインビトロで阻害する方法であって、該方法は、該細胞と、以下の構造:
- 前記細胞は癌細胞である、請求項3に記載の方法。
- 細胞内においてテロメラーゼ酵素の活性を阻害するための組成物であって、以下の構造:
- 前記細胞は癌細胞である、請求項5に記載の組成物。
- 癌細胞の増殖をインビトロで阻害する方法であって、該方法は、該細胞と、以下の構造:
- 癌細胞の増殖を阻害するための組成物であって、以下の構造:
- 薬学的に許容可能な賦形剤中に処方される、以下の構造:
- 医薬の製造のための化合物の使用であって、該化合物は、以下の構造:
- 癌を処置することにおける使用のための医薬の製造のための化合物の使用であって、該化合物は、以下の構造:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50150903P | 2003-09-09 | 2003-09-09 | |
US60/501,509 | 2003-09-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010286755A Division JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016137263A Division JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016074736A JP2016074736A (ja) | 2016-05-12 |
JP2016074736A5 true JP2016074736A5 (ja) | 2016-09-01 |
JP6158966B2 JP6158966B2 (ja) | 2017-07-05 |
Family
ID=34273050
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526347A Active JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2010286755A Active JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016014128A Active JP6158966B2 (ja) | 2003-09-09 | 2016-01-28 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2018025362A Active JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2023086871A Pending JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006526347A Active JP4690324B2 (ja) | 2003-09-09 | 2004-09-09 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2010286755A Active JP5923241B2 (ja) | 2003-09-09 | 2010-12-22 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2011274595A Pending JP2012085648A (ja) | 2003-09-09 | 2011-12-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2014087190A Pending JP2014158490A (ja) | 2003-09-09 | 2014-04-21 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016137263A Withdrawn JP2016214248A (ja) | 2003-09-09 | 2016-07-12 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2018025362A Active JP6758335B2 (ja) | 2003-09-09 | 2018-02-15 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2019131757A Withdrawn JP2019170400A (ja) | 2003-09-09 | 2019-07-17 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2021110558A Withdrawn JP2021169466A (ja) | 2003-09-09 | 2021-07-02 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
JP2023086871A Pending JP2023099808A (ja) | 2003-09-09 | 2023-05-26 | テロメラーゼ阻害のための改変オリゴヌクレオチド |
Country Status (20)
Country | Link |
---|---|
US (8) | US7494982B2 (ja) |
EP (3) | EP3682903A1 (ja) |
JP (10) | JP4690324B2 (ja) |
KR (3) | KR101319388B1 (ja) |
CN (2) | CN101293908B (ja) |
AU (2) | AU2004271215B2 (ja) |
BR (1) | BRPI0414222B8 (ja) |
CA (1) | CA2536015C (ja) |
CY (2) | CY1120113T1 (ja) |
DK (2) | DK1667522T3 (ja) |
ES (2) | ES2775525T3 (ja) |
HK (1) | HK1257622A1 (ja) |
HU (2) | HUE036593T2 (ja) |
IL (1) | IL173747A (ja) |
MX (1) | MXPA06002660A (ja) |
NZ (1) | NZ545516A (ja) |
PL (2) | PL3342425T3 (ja) |
PT (2) | PT1667522T (ja) |
SI (2) | SI3342425T1 (ja) |
WO (1) | WO2005023994A2 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0414222B8 (pt) | 2003-09-09 | 2021-05-25 | Geron Corp | compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados |
CA2544349C (en) | 2003-11-04 | 2020-02-18 | Geron Corporation | Rna amidates and thioamidates for rnai |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
ATE553198T1 (de) * | 2005-04-15 | 2012-04-15 | Geron Corp | Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US8153604B2 (en) * | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
ES2696828T3 (es) | 2006-10-30 | 2019-01-18 | Geron Corp | Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer |
WO2008094640A2 (en) | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
JP5512285B2 (ja) | 2007-02-09 | 2014-06-04 | ノースウェスタン ユニバーシティ | 細胞内標的を検出するための粒子 |
ES2407957T3 (es) | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
PL2476689T3 (pl) | 2007-05-10 | 2016-04-29 | Agilent Technologies Inc | Tiowęglowe grupy zabezpieczające do syntezy RNA |
EP2826863B1 (en) | 2007-05-30 | 2017-08-23 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
US8440809B2 (en) * | 2008-07-02 | 2013-05-14 | Santaris Pharma A/S | RNA antagonists targeting Hsp27 |
EP2175023A1 (en) * | 2008-07-31 | 2010-04-14 | The University of Zurich | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA |
LT3029154T (lt) | 2008-10-17 | 2017-12-27 | Geron Corporation | Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas |
WO2010060110A1 (en) | 2008-11-24 | 2010-05-27 | Northwestern University | Polyvalent rna-nanoparticle compositions |
BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
KR20120136345A (ko) | 2009-10-30 | 2012-12-18 | 노오쓰웨스턴 유니버시티 | 주형화된 나노컨쥬게이트 |
WO2011079290A1 (en) * | 2009-12-24 | 2011-06-30 | Northwestern University | Oligonucleotide specific uptake of nanoconjugates |
JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
WO2012135125A1 (en) | 2011-03-28 | 2012-10-04 | Geron Corporation | Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr |
CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
EP4219516A3 (en) | 2012-07-13 | 2024-01-10 | Wave Life Sciences Ltd. | Chiral control |
SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
US9228189B2 (en) | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
CA3201145A1 (en) | 2012-10-26 | 2014-05-01 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
SG11201504209YA (en) | 2012-11-30 | 2015-06-29 | Geron Corp | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
NZ708920A (en) | 2012-12-07 | 2020-08-28 | Geron Corp | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
US20140242154A1 (en) | 2013-02-22 | 2014-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds, Compositions, Methods, and Kits Relating to Telomere Extension |
AU2014292926B2 (en) | 2013-07-25 | 2020-03-05 | Exicure Operating Company | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
WO2015048558A1 (en) | 2013-09-30 | 2015-04-02 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
KR102423317B1 (ko) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
PL3164113T3 (pl) | 2014-06-04 | 2019-09-30 | Exicure, Inc. | Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CN107427592A (zh) | 2015-01-05 | 2017-12-01 | 株式会社露太利温 | 使用luterion抑制癌细胞中端粒酶的方法 |
SG11201707893RA (en) | 2015-04-23 | 2017-11-29 | Geron Corp | Methods of polynucleotide preparation using multivalent cation salt compositions |
EP3124609A1 (en) * | 2015-07-29 | 2017-02-01 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Therapeutics oligonucleotides |
DK3329004T3 (da) | 2015-07-29 | 2020-04-20 | Ifom Fondazione St Firc Di Oncologia Molecolare | Terapeutiske oligonukleotider |
MA45290A (fr) * | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
KR20190141184A (ko) * | 2017-04-20 | 2019-12-23 | 신테나 아게 | 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도 |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
UA125185C2 (uk) * | 2017-07-10 | 2022-01-26 | Джерон Корпорейшн | Покращений спосіб одержання іметелстату |
BR112020001749A2 (pt) | 2017-07-28 | 2020-07-21 | Geron Corporation | métodos de tratamento da síndrome mielodisplásica |
WO2021054370A1 (ja) * | 2019-09-18 | 2021-03-25 | 国立大学法人東京医科歯科大学 | 核酸複合体 |
IL292328A (en) | 2019-10-28 | 2022-06-01 | Geron Corp | Succinylate-converted 3-(fatty amido)-2-hydroxy-1-(hydroxy-protected)-propane salts amorphous solids and methods for their preparation |
WO2021086754A1 (en) * | 2019-10-28 | 2021-05-06 | Geron Corporation | Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same |
EP4303303A1 (en) * | 2021-03-03 | 2024-01-10 | The University of Tokyo | Acyclic threoninol nucleic acid |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
ES2055907T3 (es) * | 1989-03-07 | 1994-09-01 | Genentech Inc | Conjugados covalentes de lipidos y oligonucleotidos. |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
WO1991014696A1 (en) * | 1990-03-29 | 1991-10-03 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
US5419966A (en) * | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
CA2174425A1 (en) | 1993-10-18 | 1995-04-27 | Graham Leslie Barrett | A method for enhancing neurone survival and agents useful for same |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
CA2184375C (en) | 1994-03-18 | 2006-05-02 | Sergei M. Gryaznov | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
EP1293565A3 (en) | 1994-07-07 | 2004-05-12 | Geron Corporation | Mammalian telomerase RNA component |
US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
EP0790965A1 (en) | 1994-11-07 | 1997-08-27 | HYBRIDON, Inc. | Synthesis of ?35 s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide |
US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
AU2445997A (en) * | 1996-04-10 | 1997-10-29 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
EP0951568A1 (en) | 1996-12-20 | 1999-10-27 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
ATE391134T1 (de) | 1999-09-10 | 2008-04-15 | Geron Corp | Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung |
US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
US7563618B2 (en) * | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
BRPI0414222B8 (pt) | 2003-09-09 | 2021-05-25 | Geron Corp | compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados |
US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
US7485717B2 (en) | 2004-07-02 | 2009-02-03 | Geron Corporation | Synthesis of protected 3′-amino nucleoside monomers |
ATE553198T1 (de) | 2005-04-15 | 2012-04-15 | Geron Corp | Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten |
US8153604B2 (en) | 2006-04-24 | 2012-04-10 | Geron Corporation | CNS-tumor treatment method and composition |
ES2696828T3 (es) | 2006-10-30 | 2019-01-18 | Geron Corp | Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer |
-
2004
- 2004-09-09 BR BRPI0414222A patent/BRPI0414222B8/pt active IP Right Grant
- 2004-09-09 KR KR1020117017803A patent/KR101319388B1/ko active IP Right Grant
- 2004-09-09 EP EP19209408.4A patent/EP3682903A1/en active Pending
- 2004-09-09 AU AU2004271215A patent/AU2004271215B2/en active Active
- 2004-09-09 SI SI200432487T patent/SI3342425T1/sl unknown
- 2004-09-09 CA CA2536015A patent/CA2536015C/en active Active
- 2004-09-09 US US10/938,184 patent/US7494982B2/en active Active
- 2004-09-09 PL PL17200625T patent/PL3342425T3/pl unknown
- 2004-09-09 PT PT4783801T patent/PT1667522T/pt unknown
- 2004-09-09 ES ES17200625T patent/ES2775525T3/es active Active
- 2004-09-09 KR KR1020137007201A patent/KR101298493B1/ko active IP Right Grant
- 2004-09-09 JP JP2006526347A patent/JP4690324B2/ja active Active
- 2004-09-09 PL PL04783801T patent/PL1667522T3/pl unknown
- 2004-09-09 ES ES04783801.6T patent/ES2662196T3/es active Active
- 2004-09-09 EP EP04783801.6A patent/EP1667522B1/en active Active
- 2004-09-09 PT PT172006256T patent/PT3342425T/pt unknown
- 2004-09-09 KR KR1020067004864A patent/KR20060132802A/ko not_active Application Discontinuation
- 2004-09-09 EP EP17200625.6A patent/EP3342425B1/en active Active
- 2004-09-09 WO PCT/US2004/029718 patent/WO2005023994A2/en active Application Filing
- 2004-09-09 HU HUE04783801A patent/HUE036593T2/hu unknown
- 2004-09-09 DK DK04783801.6T patent/DK1667522T3/en active
- 2004-09-09 NZ NZ545516A patent/NZ545516A/en unknown
- 2004-09-09 MX MXPA06002660A patent/MXPA06002660A/es active IP Right Grant
- 2004-09-09 CN CN200810098490.8A patent/CN101293908B/zh active Active
- 2004-09-09 DK DK17200625.6T patent/DK3342425T3/da active
- 2004-09-09 HU HUE17200625A patent/HUE048359T2/hu unknown
- 2004-09-09 CN CNB2004800259754A patent/CN100393209C/zh active Active
- 2004-09-09 SI SI200432432T patent/SI1667522T1/en unknown
-
2006
- 2006-02-15 IL IL173747A patent/IL173747A/en active IP Right Grant
-
2008
- 2008-11-21 US US12/276,127 patent/US20090286853A1/en not_active Abandoned
-
2009
- 2009-10-07 AU AU2009222616A patent/AU2009222616A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/886,080 patent/US20120129918A1/en not_active Abandoned
- 2010-12-22 JP JP2010286755A patent/JP5923241B2/ja active Active
-
2011
- 2011-12-15 JP JP2011274595A patent/JP2012085648A/ja active Pending
-
2012
- 2012-08-21 US US13/590,511 patent/US9404112B2/en active Active
-
2014
- 2014-04-21 JP JP2014087190A patent/JP2014158490A/ja active Pending
-
2015
- 2015-05-18 US US14/714,732 patent/US9657296B2/en active Active
- 2015-05-22 US US14/720,467 patent/US9388416B2/en active Active
- 2015-05-22 US US14/720,466 patent/US9388415B2/en active Active
-
2016
- 2016-01-28 JP JP2016014128A patent/JP6158966B2/ja active Active
- 2016-06-27 US US15/194,230 patent/US10196641B2/en active Active
- 2016-07-12 JP JP2016137263A patent/JP2016214248A/ja not_active Withdrawn
-
2018
- 2018-02-15 JP JP2018025362A patent/JP6758335B2/ja active Active
- 2018-04-03 CY CY20181100365T patent/CY1120113T1/el unknown
- 2018-12-29 HK HK18116749.0A patent/HK1257622A1/zh unknown
-
2019
- 2019-07-17 JP JP2019131757A patent/JP2019170400A/ja not_active Withdrawn
-
2020
- 2020-02-26 CY CY20201100179T patent/CY1122704T1/el unknown
-
2021
- 2021-07-02 JP JP2021110558A patent/JP2021169466A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086871A patent/JP2023099808A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016074736A5 (ja) | ||
JP2011092201A5 (ja) | ||
JP2013518107A5 (ja) | ||
JP2016508134A5 (ja) | ||
JP2019511491A5 (ja) | ||
JP2012255026A5 (ja) | ||
JP2015516989A5 (ja) | ||
JP2017515901A5 (ja) | ||
CY1119880T1 (el) | Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων | |
JP2016515561A5 (ja) | ||
JP2017510610A5 (ja) | ||
JP2015078230A5 (ja) | ||
JP2018517686A5 (ja) | ||
JP2012527481A5 (ja) | ||
JP2016521119A5 (ja) | ||
JP2012144574A5 (ja) | ||
JP2019520343A5 (ja) | ||
CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
JP2009535352A5 (ja) | ||
CL2011000653A1 (es) | Compuestos derivados del acido 1-amino-2-ciclobutil-etil-boronico; composicion farmaceutica; polvo liofilizado y metodo para obtenerlo; y uso en el tratamiento del cancer. | |
JP2015512943A5 (ja) | ||
JP2016517888A5 (ja) | ||
JP2006514012A5 (ja) | ||
JP2020097577A5 (ja) | ||
JP2010523709A5 (ja) |